Objective: To investigate fetal antigen 1 (FA1) protein within the context of human obesity and its relation with insulin sensitivity. Subjects: Cross-sectional study that analyses circulating levels of FA1 in two selected human cohorts: n ¼ 127 men for the study of FA1 circulating levels in the context of obesity and insulin sensitivity (S i ); and n ¼ 61 severely obese women before and after bariatric surgery. The response in vitro to FA1 protein on human cell lines of monocytes, preadipocytes and mature adipocytes was studied. Measurements: Anthropometrical parameters: body mass index, waist-to-hip ratio, waist circumference, fat-free mass and fat mass. Clinical parameters: lipid profile (high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, total cholesterol, triglycerides), glycemic profile (fasting glucose, insulin, S i , HOMA-IR (Homeostasis Model Assessment of Insulin Resistance), cytokines (sIL-6), adipokines (adiponectin) and circulating soluble fractions of tumor necrosis factor-a receptors 1 and 2 (sTNFR1 and sTNFR2). Results: In the obesity study, levels of FA1 in serum were found to increase with obesity. The S i index was negatively dependent on FA1 levels. In severe obesity, serum levels of FA1 decreased 1.4-fold 6 months after bariatric surgery. In vitro assays with FA1 protein on human monocytes and adipocytes cell lines modified the expression of pro-inflammatory cytokines and adipokines (tumor necrosis factor-a (TNFa), monocyte chemoattractant protein-1 (MCP-1), IL-6 (interleukin-6) and adiponectin). Conclusion: FA1 serum levels were increased in obese subjects and might influence S i . The stimulatory effect of FA1 protein on pro-inflammatory cytokines on both immune and adipose cell types could contribute to worsening the inflammatory environment observed in obesity.
Introduction
Obesity occurs from the increased size of individual adipose cells due to lipid accumulation and from an increased number of adipocytes arising from the differentiation of adipose precursor mesenchymal stem cells to mature adipocytes under appropriate nutritional and hormonal signals. This precursor mesenchymal stem cell can reside in the same adipose tissue, in the bone marrow and also in other connective tissue compartments, and can differentiate to adipocytes and osteoblasts, among others.
Fetal antigen 1 (FA1) has been recently identified as a novel factor with regulatory effects on both osteoblast and adipocyte differentiation of human mesenchymal stem cells. 1 FA1 is generated by a proteolytic cleavage of the extracellular protein domain of the protein codified by the gene named 'Delta-like 1' (dlk1, also named preadipocyte factor 1 (pref-1)). Dlk1 gene encodes for a transmembrane protein with six epidermal growth factor-like repeats in its extracellular domain similar to other members of the Notch/ Delta/Serrate family, which participate in cell fate decisions during development. 2, 3 Fetal antigen 1 has been established as an inhibitor of adipocyte differentiation 2 and has an important function in determining cell fate decision in many differentiation processes, including hematopoiesis, 4 pancreatic islet cell, 5 muscle cell, 6 hepatic cell 7 and dopaminergic neurons. 8 Fetal antigen 1 is located in most embryonic and fetal tissues in humans and mice, and its expression is downregulated in postnatal stages. 9 In human adults, it is found in the glomerulosa zone of the adrenal gland, b-cells of the endocrine pancreas, the somatotroph cells of the pituitary gland, the monoaminergic neurons in the central nervous system, and in the Leydig and hilus cells of the testes and ovaries. 9, 10 FA1 is also found in most biological fluids, including urine, serum, amniotic fluid and cord serum. 11 Thus, although local tissue production of FA1 is limited in adults to the above-mentioned tissues, all tissues are exposed to circulating FA1. Biological functions that differ from the above-mentioned developmental effect have been recently studied on bone marrow mesenchymal stem cells where FA1 was found to play a role in regulating cytokine gene expression. 12 Additionally, systemic effects of FA1 on bone and fat metabolism were also determined by generating adult mice, by hydrodynamic gene transfer procedure, which overexpressed FA1. In this model, high levels of FA1 reduced both bone and fat mass in a dose-dependent manner. 13 Recently, FA1 has also been found to have an endocrinerelated function by regulating growth hormone expression in mice.
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Dlk1 gene was confirmed in vivo as an inhibitor of adipose tissue development, as null mice showed accelerated body weight gain due to an increase in adipose tissue mass, enlarged fatty liver, increased circulating levels of triglycerides, cholesterol and free fatty acids. 15 Conversely, transgenic mouse overexpressing dlk1 showed a substantial but not a complete loss of adipose tissue, hypertriglyceridemia, impaired glucose tolerance and decreased insulin sensitivity (S i ). 16 Given these emerging data on mouse models linking dlk1 with obesity, insulin-resistance and the recently identified role of FA1 in murine models as an endocrine molecule regulating fat mass in vivo, we hypothesize that FA1 could also be related to human obesity, insulin-resistance and in turn its inflammatory environment. For this purpose, we have measured circulating serum levels of FA1 in a human cohort with different degrees of obesity, and in a severe obese cohort, before and after massive weight loss due to bariatric surgery. We aimed to analyze the relationship of FA1 with selected clinical and anthropometrical parameters associated with obesity. We also aimed to analyze FA1 in relation to S i . Additionally, in vitro FA1 effect on human monocytes and differentiated adipocytes cell lines has been studied.
Methods

Obesity cohort
One hundred and twenty-seven Caucasian males were included in this study. Clinical and analytical features of the subjects are shown in Table 1 . All subjects were nondiabetic and had fasting plasma glucose o7.0 mmol l À1 levels and 2-h post-load plasma glucose o11.1 mmol l À1 after a 75-g oral glucose tolerance test following American Diabetes Association criteria. 17 With these criteria, 32% of subjects displayed impaired fasting glucose or impaired glucose 18 With these criteria, there were 27 lean, 76 overweight and 24 obese subjects. Insulin sensitivity was measured using the frequently sampled intravenous glucose tolerance test with minimal model analysis, as already described. 19 In brief, intravenous glucose (0.3 g kg
À1
) was administered at time 0, and insulin (0.03 U kg
) at time þ 20 min. The time courses of serum glucose and insulin for 3 h were analyzed using the Minimal Model Program to calculate the S i index.
Severely obese cohort
Sixty-one severely obese women scheduled for a gastric bypass were included in this study ( Table 2 ). Pre-operative and 6 months post-operative anthropometrical measurements were taken, and blood samples were collected. Patients were excluded if they had suffered from an acute major cardiovascular event in the previous 6 months, any acute illness and current evidence of acute or chronic inflammatory or infective diseases, or if they were taking any medication that could alter lipidic or metabolic parameters. Patients receiving oral treatment for diabetes or mild dyslipidemia before surgery discontinued all hypoglycemic and hypolipemic agents 1 month before surgery. Patients were always under close medical supervision to avoid any worsening of their metabolic state.
The clinical circuit established for obtaining samples in this cohort allowed us to perform HOMA-IR (Homeostasis Model Assessment of Insulin Resistance) calculation, measured as previously described, 20 as an insulin sensitivity test that has a good correlation with S i , measured by minimal model. 19 Anthropometrical, clinical and analytical methods Body mass index, waist-to-hip ratio, fat mass and fat-free mass (bioelectric impedance, Holtain BC Analyzer, Cambridge, UK), and blood pressure were measured as previously described for healthy subjects. 19 Blood samples were drawn after overnight fasting. Plasma and serum samples were stored at -80 1C until analytical measurements were performed, except for glucose and HbA 1c , which were determined immediately after the blood was drawn. Serum glucose and lipidic profile (triglycerides, total cholesterol, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol) were measured by usual methods.
Serum insulin concentration was measured in duplicate by monoclonal immunoradiometric assay (Coat-A-Count Insulin, Diagnostic Products Corporation (DPC), California, USA).
Intra-and interassay coefficients of variation were 6.6 and 7.1%, respectively.
Soluble tumor necrosis factor receptor 1 was determined by a solid phase enzyme immunoassay kit (Biosource Europe, Fleunes, Belgium). Receptor 2 (soluble tumor necrosis factor receptor 2), circulating soluble interleuking 6 (sIL-6), plasma human soluble C-reactive protein (hsCRP) and plasma adiponectin were measured as previously described.
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FA1 ELISA technique Serum FA1 was quantified using the sandwich ELISA (enzyme-linked immunosorbent assay) technique based on affinity-purified polyclonal anti-FA1 antibodies as previously described.
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Cell culture and in vitro studies The human monocytic cell line THP-1 from the European Collection of Cell Culture (Wiltshire, UK) was cultured in RPMI-1640 medium (Gibco, Invitrogen Corporation, California, USA) supplemented with 5.5 mM glucose, 10% heat-inactivated fetal calf serum, 50 mg ml À1 gentamicin, 20 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) and 3 mM glutamine, and was differentiated with 160 nM phorbol 12-myristate 13-acetate (PMA) for 24 h before use. Differentiated THP-1 was cultured for 12 h in the same medium depleted of fetal serum and stimulated for ). Cells were collected and used for RNA extraction. TNF-a, IL-6 and MCP-1 gene expressions were measured by real-time PCR relative quantification. Cytokine protein secretion in cell culture supernatants was measured by means of ELISA kits (Biotrak ELISA System, Amersham Biosciences, Buckinghamshire, UK).
Fetal antigen 1 protein used in this study was negative for contamination with lipopolysaccharide and was tested by LAL assay (Lonza Verviers, Belgium) showing 0.046 endotoxin units per ml.
The SGBS cell line was kindly provided by Dr M Wabitsch (University of Ulm, Ulm, Germany). This line is a human preadipocyte cell line with a high capacity for adipose differentiation. Cells were seeded at 3 Â 10 4 cells per cm 2 in a preadipocyte medium (Advancell, Barcelona, Spain), and 3 days later, preadipocytes were stimulated with 5 mg ml À1 FA1
for 24 h. In parallel, confluent SGBS preadipocytes were induced to differentiate to mature adipocytes in adipocyte differentiation medium (Advancell) containing 0.25 mM isobutylmethylxanthine, 1 mM dexametasone, human insulin 10 mg ml À1 and a peroxisome proliferator-activated receptor gamma (PPARg) agonist. To differentiate cells, two series of 3 days of differentiation induction with adipocyte differentiation medium were carried out. Then, 50% of the medium was replaced, every 2 days for 10 days, with adipocyte medium (Advancell) without stimuli. Mature adipocytes were stimulated for 24 h with 5 mg ml À1 FA1 in the preadipocyte medium. Preadipocyte and adipocyte cells were collected and used for RNA extraction. IL-6, MCP-1 and adiponectin (APM1) gene expression were measured by real-time PCR relative quantification.
Total RNA isolation and real-time PCR relative quantification analysis THP-1, preadipocytes and differentiated adipocytes from the SGBS human cell line were extracted using the RNAsy Mini Kit (Qiagen Science, Maryland, USA).
A quantity of 500 ng of RNA was reverse transcribed using the transcriptor first strand cDNA Synthesis Kit (Roche Diagnostics GmbH, Mannheim, Germany). Real-time PCR mRNA quantification was performed using LightCycler technology (Roche Diagnostics, Basel, Switzerland) and the SYBR green fluorescence method. The following primers were used: for IL-6, 
Statistical analysis
Statistical analysis was performed using the SPSS/PC þ statistical package (v. 13 for Windows; Chicago, Illinois, USA). An adequately powered sample size was selected for both studies. Therefore, we previously calculated the sample size necessary to obtain a statistical power of 80%. The number of experimental patients for the independent design necessary was 16 for the obesity cohort and 25 for the severely obese cohort, considering an error probability for a two-sided test of 0.05. For clinical and anthropometrical variables, normal distributed data are expressed as mean value ± s.d., and for variables with no Gaussian distribution, values are expressed as median (75th percentile). Differences between groups in clinical, laboratory parameters or plasma levels were compared using either an independent sample t-test or analysis of variance. Not normally distributed variables were logarithm transformed or non-parametric tests were used when appropriate. Differences in variables before and 6 months after surgery and in vitro experimental data were analyzed by a general linear model test. Associations between quantitative variables were evaluated by Pearson/Spearman's correlation analysis. Correction for confounding and interacting variables was performed using a stepwise multiple linear regression analysis. Results are expressed as unstandardized coefficient (B), and 95% confidence interval for B (95%CI(B) ). Statistical significance occurred if the computed two-tailed probability value was less than 0.05.
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Results
Obesity cohort
In the obesity study, levels of FA1 in serum showed significant differences between lean and obese (P ¼ 0.005) and between overweight and obese (P ¼ 0.003) subjects (Table 1) . Although no significant differences were found between lean and overweight subjects, there is a tendency toward increasing levels of FA1 with weight ( Figure 1a) .
Bivariate correlation analysis was performed to determine the interdependence or co-relationship of clinical and anthropometrical variables related with obesity and insulin-resistance. We found that FA1 circulating levels were positively associated with BMI, waist circumference, age, insulin and triglycerides (r ¼ 0.265, P ¼ 0.003; r ¼ 0.227, P ¼ 0.016; r ¼ 0.262, P ¼ 0.003; r ¼ 0.220, P ¼ 0.019; r ¼ 0.266, P ¼ 0.003, respectively), and negatively associated with high-density lipoprotein cholesterol and S i (r ¼ À0.199, FA1 in human obesity and insulin sensitivity MR Chacón et al P ¼ 0.026; r ¼ À0.264, P ¼ 0.003). Figure 2 shows the linear correlation results between S i and FA1. Then a regression model was constructed to know which of the above correlated variables were true predictors of FA1. In this model, FA1 was the dependent variable, and S i , age, BMI and triglycerides were the independent variables. We found that age (B ¼ 0. Finally, to corroborate the hypothesis as to whether FA1 levels could predict S i , a multiple regression analysis model was constructed. In this model, age, FA1 and triglycerides were included as independent variables. The result showed that FA1 was the only determinant of S i , which means that, in this model, FA1 is the only predictor of S i (B ¼ À0.374, P ¼ 0.006, 95%CI(B): À0.593-0.155).
Severely obese cohort
Fetal antigen 1 levels were measured in a cohort of severely obese subjects before and 6 months after massive weight loss due to bariatric surgery. Severely obese subjects before surgery had higher values for all the anthropometrical measurements compared with 6 months after surgery. Metabolic parameters (glucose, insulin and HbA 1c ) and lipidic parameters showed a significant decrease after surgery with near normal values at 6 months. Circulating proinflammatory markers were elevated before surgery, as shown by the high values of hsCRP, sTNFR2 and sIL-6. Adiponectin displayed normal behavior in plasma increasing with weight loss (Table 2) .
Serum levels of FA1 decreased 1.4-fold after weight loss (Po0.001) (see variation in individual cases in Figure 1b) .
In bivariate correlation analysis, FA1 levels before surgery correlated only with triglycerides (r ¼ 0.338, P ¼ 0.016). To evaluate whether metabolic or pro-inflammatory parameters could modulate FA1 circulating levels before surgery, a multivariate regression model was constructed with FA1 as the dependent variable, and hsCRP, sIL-6, glucose, insulin and triglycerides as independent ones. We found that triglyceride levels were the only determinant explaining FA1 levels before surgery (B ¼ 2, P ¼ 0.008, 95%CI(B): 1.18-6.8).
While analyzing the correlations of FA1 6 months after surgery with all the described variables, we found that FA1 correlated with age, plasma glucose levels and triglycerides To know whether FA1 decrement is predicted by weight loss or by an improvement in metabolic parameters at 6 months, we constructed a regression model including the decrement of values before and 6 months after surgery from three selected variables as independent variables (decrement of BMI, triglycerides and glucose), and FA1 decrement as the dependent variable. The FA1 decrement in this population was determined by the final weight loss and the improvement in triglycerides levels (B ¼ 0.394, P ¼ 0.004, 95%CI(B): 0.146-0.642; B ¼ 1.855, Po0.001, 95%CI(B): 1.42-2.3, respectively).
Stimulation of THP-1, preadipocytes and differentiated adipocytes cells with FA1 enhance cytokine production To obtain a localized effect of FA1 on monocytes and on preadipocytes or mature adipocytes, we tested, over a short period of time, doses up to 5 mg ml À1 of FA1 in accordance with published data. 12 We tested 1, 3 and 5 mg ml À1 of FA1 for 8 h on a THP-1 human monocytic cell line. As shown in Figure 3a , FA1 induced gene and protein expression of cytokines MCP-1, TNF-a (tumor necrosis factor-a) and IL-6 (interleukin-6).
We then tested the effect of 5 mg ml À1 FA1 on SGBS preadipocytes and differentiated adipocytes after 24 h incubation. The results are shown in Figure 3b . FA1 only had an effect on mature adipocytes, inducing an increase in gene expression of MCP-1 and IL-6 and a decrease in the expression of APM1. No stimulatory effect was seen for TNF-a (data not shown).
Discussion
Over the years, the studies on dlk1/FA1 associated with obesity and adipose tissue have been focused on mouse models, mice adipose tissue or in vitro mouse cellular models. The aim of the present investigation was to determine whether FA1 had a similar role in human obesity, and its relationship with its inflammatory and insulin-resistant environment.
In the present study, we have observed that FA1 levels increase with obesity. This data are not in accordance with previously published data on mouse models where FA1 levels increase with the loss of adipose tissue mass. FA1 in human obesity and insulin sensitivity MR Chacón et al knockouts are obese and mice overexpressing leptin show less fat mass; on the contrary, obesity in humans shows higher leptin levels which has been associated with insulinresistance, inflammation and disturbance homeostasis.
In our obesity cohort, we have observed a clear positive relationship between FA1 levels and BMI and waist circumference. These findings were corroborated in a regression model where FA1 levels were found to be positively related to age and BMI. Moreover, when we studied FA1 levels in our severely obese cohort, before and after massive weight loss, we observed a significant decrease in the circulating FA1 protein levels encompassed by decrements in inflammatory markers, adipokines and atherogenic profile indicators.
Noteworthy, the severely obese cohort, composed mainly of women, had lower FA1 levels after surgery than the male obese cohort. In this sense, we can postulate that it could be because of a sexual dimorphism in our populations; however, previous studies have shown no significant differences between genders. 11 Moreover, severely obese subjects after surgery are under a high catabolic process and there are many variables that are difficult to control. In this sense, interpretation of findings should be undertaken individually within each cohort. Variable levels of FA1 have been found to be associated with several human pathologies such as neurofibromatosis, where FA1 was found to be elevated 5 times, 22 and in renal failure, 10 times. 11 In acromegaly or growth hormone (GH) deficiency patients, FA1 levels changed after pharmacological treatment for GH. In these patients, pharmacological variation in GH levels resulted in a corresponding change in the concentration of circulating FA1. 23 In vitro analysis showed that FA1 represses GH transcription and revealing a feedback regulatory loop to keep GH function precisely modulated. 14 Human obesity has been associated with decreased GH secretion and low levels of insulin growth factor-1, 24 in this sense, we should expect lower levels of FA1 in obesity. However, our findings showed that FA1 levels increase with obesity. Human obesity is associated with a chronic low degree of inflammation where cytokines such as IL-6, TNF-a and MCP-1 play an important role. 21, 25 Similarly, changes in these cytokine levels have been involved in the pathogenesis of type 2 diabetes and cardiovascular diseases, both diseases highly linked with obesity. 25, 26 We have observed that one of the main effects of FA1 on human monocytes and adipocytes cell lines in vitro is to enhance the expression of some proinflammatory cytokines. In support of our findings, several studies have shown that FA1 is also involved in the mediation of the immunoresponse. The mechanisms concerning this regulatory function and its targets have been recently disclosed on human mesenchymal stem cells to be mediated through nuclear factor-kB. 12 Besides, we have observed that FA1 downregulates the levels of adiponectin expression in vitro, in agreement with our findings in the obesity study. This is an important fact, as it is an adipokine found to be involved in the control of fat metabolism and S i , with direct anti-diabetic, anti-atherogenic and anti-inflammatory activities. 27 Fetal antigen 1 has a pleiotropic function and is involved in many developmental and differentiation processes. Human and rat insulin b-cells have also been found to secrete FA1. Long-term exposure of rat islets to high glucose increases FA1 and insulin secretion, indicating that FA1 is regulated by glucose. 28 In our study on the obesity cohort, FA1 was inversely associated with S i and was a predictor of S i index, thus suggesting the involvement of this protein in the peripheral action of insulin. It is difficult to confer a pathogenic role for FA1 in the mechanisms related to insulin-resistance because of the transversal design of our obesity cohort; however, the experimental data in the transgenic mice model for dlk1 showed impaired insulinresistance, 16 which is in accordance with the above-mentioned clinical observations, at least in male subjects. The contribution of human subcutaneous or visceral adipose tissue to circulating FA1 is irrelevant because no gene or protein expression was detected in those tissues, nor in isolated preadipocytes or mature adipocytes (MR Chacon et al., unpublished data), subsequently other glandular tissues, such as adrenal gland, glandular pancreas, and so on, may be the main source of these circulating levels.
In conclusion, our data show for the first time FA1 serum protein in human obesity and its link to insulin-resistance. We have demonstrated, in our cohorts, that circulating levels of the soluble product FA1 are positively associated with BMI and negatively with S i exerting a stimulatory effect on proinflammatory cytokines both in immune and adipose cell types that can worsen the inflammatory environment, complicating the pathological state of the patient. The behavior observed in our study of FA1 circulating levels with respect to adiposity enables us to propose this protein as a possible candidate for further investigation as an obesity biomarker.
